Toronto, Ontario — January 16, 2026 — Leads & Copy — NuGen Medical Devices Inc. (TSXV: NGMD) has released a summary of its key developments from 2025, focusing on research and development, technical capabilities, clinical initiatives, and global commercial activities.
The company, a leader in needle-free subcutaneous drug-delivery technology, highlighted several operational achievements.
In Research & Development, NuGen demonstrated the feasibility of a Ready-to-Fill Nozzle, a component for sterile, ready-to-use pharmaceutical filling systems, aimed at supporting prefilled drug formats and the development of a prefilled solution for future integration.
The company advanced its next-generation variable-dose jet injector to better align with clinical practice and reduce training needs.
NuGen also initiated pressure-profile optimization work to improve injection comfort and consistency and progressed prototypes for its patented refill system designed for direct cartridge storage.
An animal-use injector is being advanced for release under the PetJet™ brand.
To bolster its Technical & Engineering Capacity, NuGen expanded its Netherlands design hub with new roles supporting pharma-focused device development and added two MedTech specialists in China to enhance testing, validation, and cost-effective development execution.
NuGen expanded its clinical team in France, Brazil, and Malaysia to support real-world evidence generation, local evaluations, and patient-experience initiatives.
The company also initiated the formation of a Medical Advisory Board to guide product relevance and clinical alignment.
Commercially, NuGen launched the EZIAUTOJECTOR® private-label device in the United Kingdom and secured NHS Drug Tariff approval. In Mexico, Asia, and Canada, the company continued distributor engagement, clinician feedback collection, and insurance coverage discussions.
NuGen is supporting Sol Millennium Medical Group’s participation at Pharmapack Europe 2026, showcasing NuGen’s needle-free technology.
Liang Lin, CEO of NuGen Medical Devices Inc., stated that the company’s progress in 2025 reflects the disciplined work of its teams and strengthens the foundation for continued evolution of its needle-free technology.
NuGen develops next-generation needle-free devices for subcutaneous drug delivery. Its InsuJet™ system is approved in 42 countries and aims to improve the lives of millions of people with diabetes worldwide.
Contact:
Liang Lin, Chief Executive Officer
+ 1-833-867-5557
ir@nugenmd.com
Source: NuGen Medical Devices Inc.
